KAI Pharmaceuticals Announces Initiation of Phase 1b Study of KAI-4169 for the Treatment of Secondary Hyperparathyroidism SHPT

Source :: Biotech Week. October 13, 2010, 629
Publication Year :: 2010
Abstract: KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested [...]

Subjects :: Hyperparathyroidism -- Research -- Care and treatment
Parathyroid hormone -- Research
Chronic kidney failure -- Research -- Care and treatment
Kidney diseases -- Research -- Care and treatment
Bones -- Research
Pharmaceutical industry -- Research
Biotechnology industry
Pharmaceuticals and cosmetics industries

Tools